Mayo Clinic Develops 3D-Bioprinted Human Skin Model for Preclinical Research
Researchers at Mayo Clinic have successfully developed a 3D-bioprinted human skin model to enhance preclinical testing for dermatological therapies. Led by Dr. Saranya Wyles, the team addressed limitations in traditional animal testing and short-lived human skin samples by creating a durable, layered tissue structure using bioinks containing fibroblasts, keratinocytes, and melanocytes. The innovative model utilizes plant-based recombinant collagen to avoid immune risks associated with animal-derived materials. After extensive troubleshooting to ensure cell viability and proper tissue organization, the resulting skin mimic closely replicates human skin features, including stratified layers and elasticity. This breakthrough allows for longer-term studies of chronic diseases like eczema and more accurate evaluation of treatment effects, potentially accelerating FDA applications. The technology represents a significant advancement in tissue engineering, offering a reliable alternative for drug development and reducing reliance on animal models.
Wire timeline
Mayo Clinic Develops 3D-Bioprinted Human Skin Model for Preclinical Research
Researchers at Mayo Clinic have successfully developed a 3D-bioprinted human skin model to enhance preclinical testing for dermatological therapies. Led by Dr. Saranya Wyles, the team addressed limitations in traditional animal testing and short-lived human skin samples by creating a durable, layered tissue structure using bioinks containing fibroblasts, keratinocytes, and melanocytes. The innovative model utilizes plant-based recombinant collagen to avoid immune risks associated with animal-derived materials. After extensive troubleshooting to ensure cell viability and proper tissue organization, the resulting skin mimic closely replicates human skin features, including stratified layers and elasticity. This breakthrough allows for longer-term studies of chronic diseases like eczema and more accurate evaluation of treatment effects, potentially accelerating FDA applications. The technology represents a significant advancement in tissue engineering, offering a reliable alternative for drug development and reducing reliance on animal models.
Mayo Clinic News Network